Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study-Reference-Cited by-同舟云学术

Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study

Published:2020-08-05 Issue:5 Volume:17 Page:
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Ito Tetsuhide¹²^ORCID,Fujimori Nao³,Honma Yoshitaka⁴,Kudo Atsushi⁵,Hijioka Susumu⁶,Katsushima Shinji⁷,Kimura Yasutoshi⁸,Fukutomi Akira⁹,Hisamatsu Seiichi¹⁰,Nakajima Akihiro¹⁰,Shimatsu Akira¹¹

Affiliation:

1. Department of Gastroenterology and Hepatology International University of Health and Welfare Graduate School of Medicine Fukuoka Japan

2. Neuroendocrine Tumor Centre Fukuoka Sanno Hospital Fukuoka Japan

3. Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences Kyushu University Fukuoka Japan

4. Head and Neck Medical Oncology Division and Gastrointestinal Medical Oncology Division National Cancer Center Hospital Tokyo Japan

5. Department of Hepato‐Biliary‐Pancreatic Surgery Graduate School of Medicine Tokyo Medical and Dental University Tokyo Japan

6. Department of Gastroenterology Aichi Cancer Center Hospital Nagoya Japan

7. Department of Gastroenterology National Hospital Organization Kyoto Medical Center Kyoto Japan

8. Department of Surgery Surgical Oncology and Science Sapporo Medical University Hospital Sapporo Japan

9. Gastrointestinal Oncology Shizuoka Cancer Center Shizuoka Japan

10. Pharmaceutical Research & Development Division Teijin Pharma Limited Tokyo Japan

11. Clinical Research Institute National Hospital Organization Kyoto Medical Center Kyoto Japan

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13371

Reference20 articles.

1. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis

2. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

3. Gastroenteropancreatic neuroendocrine tumours

4. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors

5. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 膵神経内分泌腫瘍（NEN）診療の現状および今後の展望;Suizo;2023-12-28

2. Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report;Folia Medica;2023-08-31

3. Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms;Nutrients;2022-12-30

4. A case of erythema multiforme-like rash induced by everolimus in a patient with a pancreatic neuroendocrine tumor;Clinical Journal of Gastroenterology;2022-10-20

5. Long action somatostatin analogues in patients with TSH-secreted pituitary adenomas: treatment experience;Obesity and metabolism;2022-02-19